Antisense modulation of CD44 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsC. Frank Bennett, Lex M. Cowsert
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of CD44. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD44. Methods of using these compounds for modulation of CD44 expression and for treatment of diseases associated with expression of CD44 are provided.
Claims24
An antisense compound 8 to 30 nucleobases in length targeted to nucleotides 5 through 22 of the 5' untranslated region;
- nucleotides 1133 through 1563 of a 3' untranslated region;
- or nucleotides 58 through 95, nucleotides 98 through 135, nucleotides 152 through 169, nucleotides 171 through 230, nucleotides 270 through 287, nucleotides 310 through 333, nucleotides 349 through 366, nucleotides 384 through 401, nucleotides 418 through 451, nucleotides 475 through 499, nucleotides 536 through 592, nucleotides 637 through 705, nucleotides 761 through 798, nucleotides 819 through 923, nucleotides 940 through 986, nucleotides 1021 through 1038 or nucleotides 1083 through 1100 of a coding region of human CD44, wherein said antisense compound specifically hybridizes with an inhibits the expression of human CD44 (SEQ ID NO:
- 1).
The antisense compound of claim 5 wherein the modified internucleotide linkage is a phosphorothioate linkage.
An antisense compound up to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO:
- 8, 11, 14, 15, 18, 21, 22, 26, 27, 33, 41, 43, 45, 51, 55, 58, 59, 60, 61, 63, 65, 66, 67, 68, 70, 77, 78, 80 or 90 which inhibits the expression of human CD44.
Dependencies are inferred from the claim text.